About
14
Publications
1,487
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
243
Citations
Publications
Publications (14)
Objectives:
Overdiagnosis of heparin-induced thrombocytopenia remains an unresolved issue in the ICU leading to the unjustified switch from heparin to alternative anticoagulants or delays in anticoagulation. Platelet function assays significantly improve the specificity of heparin-induced thrombocytopenia diagnosis, but they are not readily availa...
Hypercoagulablity is a common alteration of blood coagulation in cancer patients. However, the procoagulant activity of cancer cells is not sufficient to induce hypercoagulability. The present study was aimed to identify the mechanism with which hypercoagulabilty is produced in the presence of cancer cells. We focused on the analysis of the procoag...
Introduction
The risk of venous thromboembolism varies according to the histological type of cancer. The failure of antithrombotic treatment is more frequent in cancer patients as compared to non-cancer ones.
Aim
We aimed to elucidate the mechanism of activation of blood coagulation induced by cancer, the impact of chemo-resistance phenotype on th...
Introduction: A major problem associated with breast cancer chemotherapy is the subsequent development of resistance to chemotherapeutic agents (multidrug résistance-MDR). Hypercoagulability, increased risk of venous thromboebolism (VTE) and high rate of failure of the antithrombotic treatment with LMWHs have been observed in patients with disease...
Background:
Easy to use point of care assays for D-Dimers measurement in whole blood from patients with clinical suspicion of venous thromboembolism (VTE) will facilitate the diagnostic strategy in the emergency department (ED) setting. We prospectively evaluated the diagnostic performance of the point-of-care mLabs® Whole Blood D-Dimers test and...
In breast cancer patients VTE risk increases during chemotherapy and in advanced stage. Routine pharmacological thromboprophylaxis is not recommended but individualized risk assessment is encouraged. The incorporation of hypercoagulability biomarkers could increase the sensitivity of the risk assessment models (RAM) to identify patients at VTE risk...
Background . The protection rights of LMWHs expired or are expiring, so the extent and nature of the studies required to obtain a market authorization for LMWH copies is an issue of debate. The actual situation, which is characterized by the increasing number of enoxaparin copies available worldwide, makes the definition of criteria for the biologi...
Heparin-induced thrombocytopenia (HIT) is a potentially lethal adverse effect of heparin therapy. Accurate and rapid HIT laboratory diagnosis when HIT is suspected is crucial. The combination of an immunological assay with a functional test improves the accuracy of HIT, but functional assays are currently limited to a few laboratories. Multiplate®...
Low molecular weight heparins (LMWHs) and fondaparinux are widely used for prophylaxis and treatment of venous thromboembolic in cancer patients. However, the optimization of the antithrombotic treatment especially in patients with adenocarcinoma of the pancreas is a challenging issue. The understanding of the mechanism of action of the LMWHs and f...
Sickle cell disease (SCD) is linked to hypercoagulability and is characterised by high concentrations of erythrocyte-derived microparticles (Ed-MPs). However, the impact of procoagulant cell-derived microparticles on the thrombin generation process remains unclear. We analysed the alterations of each phase of thrombin generation (TG) in relation to...
Cancer histology influences the risk of venous thromboembolism and tissue factor (TF) is the key molecule in cancer-induced hypercoagulability. We investigated the relation between TF expression by pancreatic and breast cancer cells (BXPC3 and MCF7 respectively) and their capacity to trigger in vitro thrombin generation in normal human plasma. Flow...
4001
Poster Board III-937
Introduction
Patients with Sickle Cell Anemia (SCA) are at risk of thrombosis, but this clinical manifestation is variable and it is probably not associated with the frequency of vaso-occlusive crisis. Increased plasma levels of platelet- and erythrocyte-derived microparticles and hypercoagulability markers have been repo...
